Antiphospholipid Antibodies and COVID‐19: A Systematic Review of Clinical Implications
Immunity, Inflammation and Disease · 2025
DOI: 10.1002/iid3.70134 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Immunity, Inflammation and Disease, 2025. Verfasst von Tahereh Sabaghian und 12 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Research Development Center, Imam Hossein Educational Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Hauptthemen laut MEDLINE: COVID-19, Antibodies, Antiphospholipid, SARS-CoV-2. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 79 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: This study received a grant supported by the Research Department of the School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran (Grant….
Abstract (Originalsprache)
Introduction
As the COVID‐19 pandemic transitions, understanding the intricate dynamics of the disease becomes paramount. This systematic review explores the role of antiphospholipid antibodies in COVID‐19, focusing on their potential clinical implications.
Methods
This systematic review, following PRISMA guidelines, assesses studies exploring the link between antiphospholipid antibodies and COVID‐19. PubMed/Medline, Embase, and Scopus were searched for relevant studies published up to December 22, 2024. Inclusion criteria comprised studies involving patients diagnosed with COVID‐19 and reporting on the presence of antiphospholipid antibodies. The risk of bias in individual studies was evaluated using the Joanna Briggs Institute appraisal tool.
Results
Our Study includes 59 records involving a total of 28,489 COVID‐19 patients. Antiphospholipid antibodies were tested in 14,498 COVID‐19 patients. It was observed that 50.84% of patients tested positive for antiphospholipid antibodies. Various types of antiphospholipid antibodies, including Anticardiolipin, Anti beta2 glycoproteins, and Lupus anticoagulant antibody, displayed prevalence rates in the patients with thrombosis. The overall frequency of antiphospholipid antibodies in thrombosis patients was 38.55%.
Conclusion
The presence of antiphospholipid antibodies in a significant proportion of COVID‐19 patients underscores the need for a detailed investigation into their role in thrombotic events. Our study highlights potential avenues for targeted interventions. However, the evolving nature of COVID‐19 necessitates continued research efforts to clarify clinical implications and optimize management strategies in this complex landscape of thrombosis and immunology. The review reveals some limitations, such as variability in study designs and demographics and inherent differences in methodologies among included studies. Future studies should address these limitations with standardized methodologies for more conclusive findings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Research Development Center, Imam Hossein Educational Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
- Department of Internal Medicine, School of Medicine, Imam Hossein Medical Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
- Department of Cardiology, Imam Hossein Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
- Department of Microbiology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
- Servizio di Epidemiologia Clinica delle Malattie Respiratorie, Istituti Clinici Scientifici Maugeri IRCCS, Tradate, Italy.
- Public Health Consulting Group, Lugano, Switzerland.
ORCID-Profile: Amir Behnam Kharazmi, Mohammad Javad Nasiri
Förderung
- This study received a grant supported by the Research Department of the School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran (Grant…
Zitieren
APA
Sabaghian, T., Kharazmi, A. B., Omidi, F., Hajikhani, B., Tehrani, S., Mardani, S., Shahidi Bonjar, A. H., Centis, R., D'Ambrosio, L., Sotgiu, G., Fabio, A., Nasiri, M. J., & Migliori, G. B. (2025). Antiphospholipid Antibodies and COVID‐19: A Systematic Review of Clinical Implications. Immunity, Inflammation and Disease. https://doi.org/10.1002/iid3.70134
Vancouver
Sabaghian T, Kharazmi AB, Omidi F, Hajikhani B, Tehrani S, Mardani S, et al. Antiphospholipid Antibodies and COVID‐19: A Systematic Review of Clinical Implications. Immunity, Inflammation and Disease. 2025. doi:10.1002/iid3.70134
BibTeX
@article{Sabaghian2025,
author = {Sabaghian, Tahereh and Kharazmi, Amir Behnam and Omidi, Fatemeh and Hajikhani, Bahareh and Tehrani, Shabnam and Mardani, Sayna and Shahidi Bonjar, Amir Hashem and Centis, Rosella and D'Ambrosio, Lia and Sotgiu, Giovanni and Fabio, Angeli and Nasiri, Mohammad Javad and Migliori, Giovanni Battista},
title = {Antiphospholipid Antibodies and COVID‐19: A Systematic Review of Clinical Implications},
journal = {Immunity, Inflammation and Disease},
year = {2025},
doi = {10.1002/iid3.70134}
}
EUVIMED